Form 4: Cross Country Healthcare Director Receives Equity Grant

Cross Country Healthcare Director Kevin Clark was granted 162,672 restricted shares of common stock following a terminated merger agreement.

Summary

• Kevin Cronin Clark, a Director at Cross Country Healthcare Inc. (CCRN), acquired 162,672 restricted shares of common stock (RSAs) on December 18, 2025.
• The RSAs were granted at a price of $0 and will vest in three substantially equal installments on December 18, 2026, March 31, 2027, and March 31, 2028.
• This grant was approved by the Company's Compensation Committee following the termination of a Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025.
• The vesting schedule was adjusted to align with previously granted RSAs, with the initial vesting 12 months from the grant date and subsequent vestings on March 31 of the two subsequent years.
• Following this transaction, Mr. Clark directly beneficially owns 809,170 shares of common stock.
• Additionally, 3,961 shares are indirectly beneficially owned by Mr. Clark's spouse, with Mr. Clark disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the grant itself is a positive for the director and aligns interests, the underlying context of a terminated merger introduces a degree of uncertainty or a past negative event. The grant is a standard compensation mechanism rather than a direct indicator of immediate operational success or failure.

Positives

• A significant equity grant to a director aligns management's interests with those of shareholders, potentially incentivizing long-term performance.
• The Compensation Committee's approval of the grant demonstrates ongoing commitment to executive compensation and retention post-merger termination.

Negatives

• The grant of restricted shares is a direct consequence of a terminated merger agreement, which could be viewed as a negative event for the company's strategic direction or growth prospects.

Risks

• The termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025, could indicate potential strategic or operational challenges for Cross Country Healthcare Inc.

Future Outlook

The company has established a vesting schedule for the granted restricted shares extending through March 2028, indicating a long-term retention strategy for its director. The adjustment of vesting dates to coincide with previously granted RSAs suggests an effort to standardize equity compensation practices.

Management Comments

• The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.
• After the initial vesting date 12 months from the grant date, the remaining RSAs will vest on March 31 of the two subsequent years to coincide with the vesting dates of the Company's previously granted RSAs.

Industry Context

In the healthcare staffing industry, equity grants are a common tool for executive and director compensation, aiming to align leadership incentives with long-term company performance. The termination of a significant merger agreement, as seen here, can lead to adjustments in compensation strategies as companies recalibrate their strategic direction and focus on internal growth or alternative M&A opportunities.

Comparison to Industry Standards

• The grant of restricted stock awards (RSAs) with a multi-year vesting schedule is a standard practice in executive and director compensation across various industries, including healthcare staffing, to promote long-term commitment and performance.
• The specific value of the grant (162,672 shares) would need to be benchmarked against similar grants to directors at comparable healthcare staffing companies (e.g., AMN Healthcare Services, Inc., Health Carousel) to assess its relative size and competitiveness, though the filing does not provide such comparative data.

Corporate Governance

Related Party Transactions

• 3,961 shares are indirectly beneficially owned by Mr. Clark's spouse. Mr. Clark disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director aligns his interests with long-term shareholder value creation, as the value of his compensation is tied to the company's stock performance.
• Employees: While not directly impacting all employees, the compensation structure for directors can set a precedent or reflect the overall compensation philosophy within the company.

Next Steps

• The restricted shares will vest in three installments on December 18, 2026, March 31, 2027, and March 31, 2028.

Key Dates

Keywords

Cross Country Healthcare, CCRN, Kevin Clark, Restricted Stock Award, RSA, Insider Transaction, Form 4, Equity Grant, Director Compensation, Merger Termination